Prognostic Significance of Thrombomodulin mRNA in High‐Grade Soft Tissue Sarcomas after 10 years
Objective To elucidate the correlation between expression of thrombomodulin (TM) mRNA from 83 benign soft tissue tumors or soft tissue sarcomas (STS) and clinicopathological parameters and to analyze the outcome of high‐grade STS patients after 10 years. Methods Total RNA was extracted from 83 prima...
Gespeichert in:
| Veröffentlicht in: | Orthopaedic surgery 2020-12, Vol.12 (6), p.1726-1732 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1732 |
|---|---|
| container_issue | 6 |
| container_start_page | 1726 |
| container_title | Orthopaedic surgery |
| container_volume | 12 |
| creator | Asanuma, Kunihiro Nakamura, Tomoki Asanuma, Yumiko Okamoto, Takayuki Kakimoto, Takuya Yada, Yuki Hagi, Tomohito Kita, Kouji Nakamura, Koichi Matsumine, Akihiko Sudo, Akihiro |
| description | Objective
To elucidate the correlation between expression of thrombomodulin (TM) mRNA from 83 benign soft tissue tumors or soft tissue sarcomas (STS) and clinicopathological parameters and to analyze the outcome of high‐grade STS patients after 10 years.
Methods
Total RNA was extracted from 83 primary soft tissue tumors (15 benign tumors, 68 STS). TM mRNA normalized to glyceraldehyde‐3‐phosphate dehydrogenase was measured with real‐time quantitative polymerase chain reaction and compared to various clinicopathological parameters. The log‐rank test and Cox proportional hazard analysis were used to evaluate recurrence‐free survival, metastasis‐free survival, and overall survival.
Results
Thrombomodulin mRNA levels were not significantly different between benign tumors and STS. In STS, TM mRNA levels were not significantly different between histologically high‐grade (n = 57) and low‐grade (n = 11) tumors. Following analysis of high‐grade STS at the 10‐year follow‐up, 21 patients had experienced a recurrence, 22 patients had experienced metastasis, and 23 patients had died of disease (DOD). TM levels were significantly higher in patients with metastasis or DOD patients. Receiver operating characteristic analysis for identifying 5‐year and 10‐year DOD determined the threshold for best sensitivity and specificity as 0.283. We divided patients into those with high ( |
| doi_str_mv | 10.1111/os.12779 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7767767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2472937295</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3809-7c7c3c149c9c8e6cdfbebf0de410990df64a4b896ca977909052760a62a612423</originalsourceid><addsrcrecordid>eNp1kctKAzEUhoMo3sEnkIAbN1OTuSSTjVCKVkFUbF2HTCZpI51JTWaU7ty68xn7JKaOFl0YAudAPr6c5AfgCKMeDuvM-h6OKWUbYBfTjEY0J3hz3WfJDtjz_gkhwhJKt8FOkiCcsZzugvLe2UltfWMkHJlJbbSRopYKWg3HU2erwla2bGemhtXDbR-GemUm0-Xbx9CJUsGR1Q0cG-_b0AsnbSU8FLpRDmK0fHtfKOH8AdjSYubV4XfdB4-XF-PBVXRzN7we9G8imeSIRVRSmUicMslkrogsdaEKjUqVYsQYKjVJRVrkjEjBwmMRQ1lMCRIkFgTHaZzsg_POO2-LSpVS1Y0TMz53phJuwa0w_O9JbaZ8Yl84pWS1g-DkW-Dsc6t8w59s6-owM49TGoffi1kWqNOOks5675Re34ARX-XBredfeQT0-PdEa_AngABEHfBqZmrxr4jfjTrhJwHflmI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2472937295</pqid></control><display><type>article</type><title>Prognostic Significance of Thrombomodulin mRNA in High‐Grade Soft Tissue Sarcomas after 10 years</title><source>Wiley Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Asanuma, Kunihiro ; Nakamura, Tomoki ; Asanuma, Yumiko ; Okamoto, Takayuki ; Kakimoto, Takuya ; Yada, Yuki ; Hagi, Tomohito ; Kita, Kouji ; Nakamura, Koichi ; Matsumine, Akihiko ; Sudo, Akihiro</creator><creatorcontrib>Asanuma, Kunihiro ; Nakamura, Tomoki ; Asanuma, Yumiko ; Okamoto, Takayuki ; Kakimoto, Takuya ; Yada, Yuki ; Hagi, Tomohito ; Kita, Kouji ; Nakamura, Koichi ; Matsumine, Akihiko ; Sudo, Akihiro</creatorcontrib><description>Objective
To elucidate the correlation between expression of thrombomodulin (TM) mRNA from 83 benign soft tissue tumors or soft tissue sarcomas (STS) and clinicopathological parameters and to analyze the outcome of high‐grade STS patients after 10 years.
Methods
Total RNA was extracted from 83 primary soft tissue tumors (15 benign tumors, 68 STS). TM mRNA normalized to glyceraldehyde‐3‐phosphate dehydrogenase was measured with real‐time quantitative polymerase chain reaction and compared to various clinicopathological parameters. The log‐rank test and Cox proportional hazard analysis were used to evaluate recurrence‐free survival, metastasis‐free survival, and overall survival.
Results
Thrombomodulin mRNA levels were not significantly different between benign tumors and STS. In STS, TM mRNA levels were not significantly different between histologically high‐grade (n = 57) and low‐grade (n = 11) tumors. Following analysis of high‐grade STS at the 10‐year follow‐up, 21 patients had experienced a recurrence, 22 patients had experienced metastasis, and 23 patients had died of disease (DOD). TM levels were significantly higher in patients with metastasis or DOD patients. Receiver operating characteristic analysis for identifying 5‐year and 10‐year DOD determined the threshold for best sensitivity and specificity as 0.283. We divided patients into those with high (<0.283) and low (≤0.283) TM mRNA levels. Based on Kaplan–Meier analysis, a significant difference between the two groups was seen for recurrence‐free survival (5 years: low = 76.6%, high = 53.1%, 10 years: low: 67.0%, high 39.8%, P = 0.0122) and metastasis‐free survival (5 years: low = 86.3%, high = 40.2%, 10 years: low: 73.3%, high: 35.2%, P = 0.00023). Furthermore, the high TM group showed significantly worse prognosis than the low TM group (5 years: low = 90.1%, high = 42.3%, 10 years: low: 76.4%, high 31.3%, P = 0.00031). Thus, high levels of TM mRNA are associated with highly recurrent and metastatic potential and lead to poor prognosis. In multivariate Cox proportional hazard analysis, only high TM showed a significant difference in metastasis‐free survival (hazard ratio: 4.33, 95% confidence interval 1.61–11.6, P = 0.00359) and overall survival (hazard ratio: 3.69, 95% confidence interval 1.49–10.5, P = 0.00569).
Conclusion
High levels of TM mRNA may be a significant predictor of recurrence, metastasis, and a poor outcome in STS patients after 10 years. TM is a candidate molecular marker and may be clinically useful for devising a therapeutic treatment strategy by prediction of prognosis.</description><identifier>ISSN: 1757-7853</identifier><identifier>EISSN: 1757-7861</identifier><identifier>DOI: 10.1111/os.12779</identifier><identifier>PMID: 33015987</identifier><language>eng</language><publisher>Melbourne: John Wiley & Sons Australia, Ltd</publisher><subject>Age ; Bladder cancer ; Bone surgery ; Cell adhesion & migration ; Clinical ; Females ; Gene expression ; Lung cancer ; Medical prognosis ; Metastasis ; Mortality ; mRNA ; Patients ; Polymerase chain reaction ; Prognosis ; Radiation therapy ; Sarcoma ; Soft tissue sarcoma ; Soft tissue tumor ; Thrombomodulin ; Tumors ; Values</subject><ispartof>Orthopaedic surgery, 2020-12, Vol.12 (6), p.1726-1732</ispartof><rights>2020 The Authors. published by Chinese Orthopaedic Association and John Wiley & Sons Australia, Ltd.</rights><rights>2020 The Authors. Orthopaedic Surgery published by Chinese Orthopaedic Association and John Wiley & Sons Australia, Ltd.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3809-7c7c3c149c9c8e6cdfbebf0de410990df64a4b896ca977909052760a62a612423</cites><orcidid>0000-0002-1244-0236</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767767/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767767/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33015987$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Asanuma, Kunihiro</creatorcontrib><creatorcontrib>Nakamura, Tomoki</creatorcontrib><creatorcontrib>Asanuma, Yumiko</creatorcontrib><creatorcontrib>Okamoto, Takayuki</creatorcontrib><creatorcontrib>Kakimoto, Takuya</creatorcontrib><creatorcontrib>Yada, Yuki</creatorcontrib><creatorcontrib>Hagi, Tomohito</creatorcontrib><creatorcontrib>Kita, Kouji</creatorcontrib><creatorcontrib>Nakamura, Koichi</creatorcontrib><creatorcontrib>Matsumine, Akihiko</creatorcontrib><creatorcontrib>Sudo, Akihiro</creatorcontrib><title>Prognostic Significance of Thrombomodulin mRNA in High‐Grade Soft Tissue Sarcomas after 10 years</title><title>Orthopaedic surgery</title><addtitle>Orthop Surg</addtitle><description>Objective
To elucidate the correlation between expression of thrombomodulin (TM) mRNA from 83 benign soft tissue tumors or soft tissue sarcomas (STS) and clinicopathological parameters and to analyze the outcome of high‐grade STS patients after 10 years.
Methods
Total RNA was extracted from 83 primary soft tissue tumors (15 benign tumors, 68 STS). TM mRNA normalized to glyceraldehyde‐3‐phosphate dehydrogenase was measured with real‐time quantitative polymerase chain reaction and compared to various clinicopathological parameters. The log‐rank test and Cox proportional hazard analysis were used to evaluate recurrence‐free survival, metastasis‐free survival, and overall survival.
Results
Thrombomodulin mRNA levels were not significantly different between benign tumors and STS. In STS, TM mRNA levels were not significantly different between histologically high‐grade (n = 57) and low‐grade (n = 11) tumors. Following analysis of high‐grade STS at the 10‐year follow‐up, 21 patients had experienced a recurrence, 22 patients had experienced metastasis, and 23 patients had died of disease (DOD). TM levels were significantly higher in patients with metastasis or DOD patients. Receiver operating characteristic analysis for identifying 5‐year and 10‐year DOD determined the threshold for best sensitivity and specificity as 0.283. We divided patients into those with high (<0.283) and low (≤0.283) TM mRNA levels. Based on Kaplan–Meier analysis, a significant difference between the two groups was seen for recurrence‐free survival (5 years: low = 76.6%, high = 53.1%, 10 years: low: 67.0%, high 39.8%, P = 0.0122) and metastasis‐free survival (5 years: low = 86.3%, high = 40.2%, 10 years: low: 73.3%, high: 35.2%, P = 0.00023). Furthermore, the high TM group showed significantly worse prognosis than the low TM group (5 years: low = 90.1%, high = 42.3%, 10 years: low: 76.4%, high 31.3%, P = 0.00031). Thus, high levels of TM mRNA are associated with highly recurrent and metastatic potential and lead to poor prognosis. In multivariate Cox proportional hazard analysis, only high TM showed a significant difference in metastasis‐free survival (hazard ratio: 4.33, 95% confidence interval 1.61–11.6, P = 0.00359) and overall survival (hazard ratio: 3.69, 95% confidence interval 1.49–10.5, P = 0.00569).
Conclusion
High levels of TM mRNA may be a significant predictor of recurrence, metastasis, and a poor outcome in STS patients after 10 years. TM is a candidate molecular marker and may be clinically useful for devising a therapeutic treatment strategy by prediction of prognosis.</description><subject>Age</subject><subject>Bladder cancer</subject><subject>Bone surgery</subject><subject>Cell adhesion & migration</subject><subject>Clinical</subject><subject>Females</subject><subject>Gene expression</subject><subject>Lung cancer</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>mRNA</subject><subject>Patients</subject><subject>Polymerase chain reaction</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Sarcoma</subject><subject>Soft tissue sarcoma</subject><subject>Soft tissue tumor</subject><subject>Thrombomodulin</subject><subject>Tumors</subject><subject>Values</subject><issn>1757-7853</issn><issn>1757-7861</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kctKAzEUhoMo3sEnkIAbN1OTuSSTjVCKVkFUbF2HTCZpI51JTWaU7ty68xn7JKaOFl0YAudAPr6c5AfgCKMeDuvM-h6OKWUbYBfTjEY0J3hz3WfJDtjz_gkhwhJKt8FOkiCcsZzugvLe2UltfWMkHJlJbbSRopYKWg3HU2erwla2bGemhtXDbR-GemUm0-Xbx9CJUsGR1Q0cG-_b0AsnbSU8FLpRDmK0fHtfKOH8AdjSYubV4XfdB4-XF-PBVXRzN7we9G8imeSIRVRSmUicMslkrogsdaEKjUqVYsQYKjVJRVrkjEjBwmMRQ1lMCRIkFgTHaZzsg_POO2-LSpVS1Y0TMz53phJuwa0w_O9JbaZ8Yl84pWS1g-DkW-Dsc6t8w59s6-owM49TGoffi1kWqNOOks5675Re34ARX-XBredfeQT0-PdEa_AngABEHfBqZmrxr4jfjTrhJwHflmI</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Asanuma, Kunihiro</creator><creator>Nakamura, Tomoki</creator><creator>Asanuma, Yumiko</creator><creator>Okamoto, Takayuki</creator><creator>Kakimoto, Takuya</creator><creator>Yada, Yuki</creator><creator>Hagi, Tomohito</creator><creator>Kita, Kouji</creator><creator>Nakamura, Koichi</creator><creator>Matsumine, Akihiko</creator><creator>Sudo, Akihiro</creator><general>John Wiley & Sons Australia, Ltd</general><general>John Wiley & Sons, Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1244-0236</orcidid></search><sort><creationdate>202012</creationdate><title>Prognostic Significance of Thrombomodulin mRNA in High‐Grade Soft Tissue Sarcomas after 10 years</title><author>Asanuma, Kunihiro ; Nakamura, Tomoki ; Asanuma, Yumiko ; Okamoto, Takayuki ; Kakimoto, Takuya ; Yada, Yuki ; Hagi, Tomohito ; Kita, Kouji ; Nakamura, Koichi ; Matsumine, Akihiko ; Sudo, Akihiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3809-7c7c3c149c9c8e6cdfbebf0de410990df64a4b896ca977909052760a62a612423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age</topic><topic>Bladder cancer</topic><topic>Bone surgery</topic><topic>Cell adhesion & migration</topic><topic>Clinical</topic><topic>Females</topic><topic>Gene expression</topic><topic>Lung cancer</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>mRNA</topic><topic>Patients</topic><topic>Polymerase chain reaction</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Sarcoma</topic><topic>Soft tissue sarcoma</topic><topic>Soft tissue tumor</topic><topic>Thrombomodulin</topic><topic>Tumors</topic><topic>Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Asanuma, Kunihiro</creatorcontrib><creatorcontrib>Nakamura, Tomoki</creatorcontrib><creatorcontrib>Asanuma, Yumiko</creatorcontrib><creatorcontrib>Okamoto, Takayuki</creatorcontrib><creatorcontrib>Kakimoto, Takuya</creatorcontrib><creatorcontrib>Yada, Yuki</creatorcontrib><creatorcontrib>Hagi, Tomohito</creatorcontrib><creatorcontrib>Kita, Kouji</creatorcontrib><creatorcontrib>Nakamura, Koichi</creatorcontrib><creatorcontrib>Matsumine, Akihiko</creatorcontrib><creatorcontrib>Sudo, Akihiro</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Orthopaedic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Asanuma, Kunihiro</au><au>Nakamura, Tomoki</au><au>Asanuma, Yumiko</au><au>Okamoto, Takayuki</au><au>Kakimoto, Takuya</au><au>Yada, Yuki</au><au>Hagi, Tomohito</au><au>Kita, Kouji</au><au>Nakamura, Koichi</au><au>Matsumine, Akihiko</au><au>Sudo, Akihiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Significance of Thrombomodulin mRNA in High‐Grade Soft Tissue Sarcomas after 10 years</atitle><jtitle>Orthopaedic surgery</jtitle><addtitle>Orthop Surg</addtitle><date>2020-12</date><risdate>2020</risdate><volume>12</volume><issue>6</issue><spage>1726</spage><epage>1732</epage><pages>1726-1732</pages><issn>1757-7853</issn><eissn>1757-7861</eissn><abstract>Objective
To elucidate the correlation between expression of thrombomodulin (TM) mRNA from 83 benign soft tissue tumors or soft tissue sarcomas (STS) and clinicopathological parameters and to analyze the outcome of high‐grade STS patients after 10 years.
Methods
Total RNA was extracted from 83 primary soft tissue tumors (15 benign tumors, 68 STS). TM mRNA normalized to glyceraldehyde‐3‐phosphate dehydrogenase was measured with real‐time quantitative polymerase chain reaction and compared to various clinicopathological parameters. The log‐rank test and Cox proportional hazard analysis were used to evaluate recurrence‐free survival, metastasis‐free survival, and overall survival.
Results
Thrombomodulin mRNA levels were not significantly different between benign tumors and STS. In STS, TM mRNA levels were not significantly different between histologically high‐grade (n = 57) and low‐grade (n = 11) tumors. Following analysis of high‐grade STS at the 10‐year follow‐up, 21 patients had experienced a recurrence, 22 patients had experienced metastasis, and 23 patients had died of disease (DOD). TM levels were significantly higher in patients with metastasis or DOD patients. Receiver operating characteristic analysis for identifying 5‐year and 10‐year DOD determined the threshold for best sensitivity and specificity as 0.283. We divided patients into those with high (<0.283) and low (≤0.283) TM mRNA levels. Based on Kaplan–Meier analysis, a significant difference between the two groups was seen for recurrence‐free survival (5 years: low = 76.6%, high = 53.1%, 10 years: low: 67.0%, high 39.8%, P = 0.0122) and metastasis‐free survival (5 years: low = 86.3%, high = 40.2%, 10 years: low: 73.3%, high: 35.2%, P = 0.00023). Furthermore, the high TM group showed significantly worse prognosis than the low TM group (5 years: low = 90.1%, high = 42.3%, 10 years: low: 76.4%, high 31.3%, P = 0.00031). Thus, high levels of TM mRNA are associated with highly recurrent and metastatic potential and lead to poor prognosis. In multivariate Cox proportional hazard analysis, only high TM showed a significant difference in metastasis‐free survival (hazard ratio: 4.33, 95% confidence interval 1.61–11.6, P = 0.00359) and overall survival (hazard ratio: 3.69, 95% confidence interval 1.49–10.5, P = 0.00569).
Conclusion
High levels of TM mRNA may be a significant predictor of recurrence, metastasis, and a poor outcome in STS patients after 10 years. TM is a candidate molecular marker and may be clinically useful for devising a therapeutic treatment strategy by prediction of prognosis.</abstract><cop>Melbourne</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>33015987</pmid><doi>10.1111/os.12779</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1244-0236</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1757-7853 |
| ispartof | Orthopaedic surgery, 2020-12, Vol.12 (6), p.1726-1732 |
| issn | 1757-7853 1757-7861 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7767767 |
| source | Wiley Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central |
| subjects | Age Bladder cancer Bone surgery Cell adhesion & migration Clinical Females Gene expression Lung cancer Medical prognosis Metastasis Mortality mRNA Patients Polymerase chain reaction Prognosis Radiation therapy Sarcoma Soft tissue sarcoma Soft tissue tumor Thrombomodulin Tumors Values |
| title | Prognostic Significance of Thrombomodulin mRNA in High‐Grade Soft Tissue Sarcomas after 10 years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A37%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Significance%20of%20Thrombomodulin%20mRNA%20in%20High%E2%80%90Grade%20Soft%20Tissue%20Sarcomas%20after%2010%E2%80%89years&rft.jtitle=Orthopaedic%20surgery&rft.au=Asanuma,%20Kunihiro&rft.date=2020-12&rft.volume=12&rft.issue=6&rft.spage=1726&rft.epage=1732&rft.pages=1726-1732&rft.issn=1757-7853&rft.eissn=1757-7861&rft_id=info:doi/10.1111/os.12779&rft_dat=%3Cproquest_pubme%3E2472937295%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2472937295&rft_id=info:pmid/33015987&rfr_iscdi=true |